Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1997 1
1998 6
1999 2
2001 2
2002 1
2003 2
2004 3
2005 9
2006 4
2007 4
2008 3
2009 3
2010 7
2011 7
2012 10
2013 5
2014 2
2015 3
2016 7
2017 3
2018 1
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Results by year
Filters applied: . Clear all
Page 1
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
Gisselbrecht C, et al. J Clin Oncol 2010 - Clinical Trial. Among authors: Ketterer N. PMID 20660832 Free PMC article.
RESULTS: The median age of the 396 patients enrolled (R-ICE, n = 202; R-DHAP, n = 194) was 55 years. Similar response rates were observed after three cycles of R-ICE (63.5%; 95% CI, 56% to 70%) and R-DHAP (62.8%; 95 CI, 55% to 69%). ...
RESULTS: The median age of the 396 patients enrolled (R-ICE, n = 202; R-DHAP, n = 194) was 55 years. Similar response rates we …
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Maurer MJ, et al. J Clin Oncol 2018. Among authors: Ketterer N. PMID 29672223 Free PMC article.
Patients and Methods Patients were prospectively enrolled in the University of Iowa and Mayo Clinic Specialized Programs of Research Excellence Molecular Epidemiology Resource (MER; N = 986) or the Lymphoma Study Association (LYSA) LNH-2003 clinical trials program (N = 1,444). ...
Patients and Methods Patients were prospectively enrolled in the University of Iowa and Mayo Clinic Specialized Programs of Research Excelle …
Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)
Voegeli M, et al. Hematol Oncol 2017 - Clinical Trial. Among authors: Ketterer N. PMID 27677906
Seven patients did not complete treatment because of mobilization failure (n = 3), progressive disease (n = 2), worsening of cardiac function (n = 1), and grade 3 dyspnea (n = 1). ...Nonhematological grade 3 or higher treatment related adverse events (AEs) were infection (n = 6), including 2 cases of febrile neutropenia, diarrhea (n = 3), mucositis, anorexia, viral hepatitis, hypokalemia, dehydration, and multiorgan failure (n = 1 for each). ...
Seven patients did not complete treatment because of mobilization failure (n = 3), progressive disease (n = 2), worsening of c …
76 results
Jump to page
Feedback